<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00217711</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 41/03</org_study_id>
    <secondary_id>EU-20524</secondary_id>
    <nct_id>NCT00217711</nct_id>
  </id_info>
  <brief_title>Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>Oxaliplatin, Irinotecan, and Capecitabine as a Combination Regimen for First-Line Treatment of Advanced or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, and capecitabine,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of capecitabine&#xD;
      when given together with oxaliplatin and irinotecan and to see how well they work in treating&#xD;
      patients with advanced or metastatic colorectal cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of capecitabine&#xD;
           administered in combination with oxaliplatin and irinotecan in patients with&#xD;
           unresectable advanced or metastatic colorectal cancer. (Phase I)&#xD;
&#xD;
        -  Determine the efficacy of this regimen in these patients. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the tolerability of this regimen in these patients. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I dose-escalation study of capecitabine followed by a&#xD;
      phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive oxaliplatin IV over 2 hours on days 1 and 15, irinotecan IV&#xD;
           over 1 hour on days 8 and 22, and oral capecitabine twice daily on days 1-29. Treatment&#xD;
           repeats every 5 weeks for up to 6 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive capecitabine at the MTD and irinotecan and oxaliplatin as in&#xD;
           phase I.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 2 months for 1 year and then&#xD;
      every 4 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 23-32 patients (3-12 for the phase I portion and 20 for the&#xD;
      phase II portion) will be accrued for this study within 2.75 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>capecitabine + oxaliplatin + irinotecan dose finding</measure>
    <time_frame>30 days</time_frame>
    <description>Determine the maximum tolerated dose and recommended phase II dose of capecitabine administered in combination with oxaliplatin and irinotecan in patients with unresectable advanced or metastatic colorectal cancer. (Phase I)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Oxaliplatin, Irinotecan, and Capecitabine</measure>
    <time_frame>2 months</time_frame>
    <description>Determine the efficacy of this regimen in these patients (Phase II)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response (CR or PR) as measured after completion of study treatment</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events as measured after completion of study treatment</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>life-long</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure as measured after completion of study treatment</measure>
    <time_frame>life-long</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>life-long</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxaliplatin, Irinotecan, and Capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>capecitabine</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>irinotecan hydrochloride</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>oxaliplatin</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed unresectable advanced or metastatic&#xD;
             colorectal cancer&#xD;
&#xD;
          -  Measurable disease (phase II only)&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques&#xD;
                  OR ≥ 10 mm by spiral CT scan or MRI&#xD;
&#xD;
          -  No presence or history of CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 70&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.25 times upper limit of normal (ULN) (1.5 times ULN if liver metastases&#xD;
             are present)&#xD;
&#xD;
          -  AST and ALT ≤ 3 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III-IV congestive heart failure&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No other clinically significant cardiac disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No active autoimmune disease&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No prior severe reaction to fluoropyrimidine therapy or known hypersensitivity to&#xD;
             fluorouracil&#xD;
&#xD;
          -  No known hypersensitivity to any component of study drugs&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Patients must use effective contraception during and for 1 year after study&#xD;
             participation&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated carcinoma in&#xD;
             situ of the cervix or localized nonmelanoma skin cancer&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1 of any origin (e.g., alcohol or diabetes)&#xD;
&#xD;
          -  No nausea, vomiting, or malabsorption syndrome that would preclude ingestion or&#xD;
             absorption of oral medication&#xD;
&#xD;
          -  No psychiatric disability that would preclude study compliance&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No other serious underlying medical condition that would preclude study participation&#xD;
&#xD;
          -  No known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic hematopoietic growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 6 months since prior adjuvant fluoropyrimidine chemotherapy&#xD;
&#xD;
          -  No other prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
               -  Concurrent radiotherapy of a single painful lesion allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior clinical trial participation&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent sorivudine or its chemically-related analogues (e.g., lamivudine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Razvan Popescu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik Aarau</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>von Moos R, Roth A, Ruhstaller T, Widmer L, Uhlmann C, Cathomas R, Köberle D, Simcock M, Lanz D, Popescu R. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). Onkologie. 2010;33(6):295-9. doi: 10.1159/000313598. Epub 2010 May 14.</citation>
    <PMID>20523092</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>June 2, 2012</last_update_submitted>
  <last_update_submitted_qc>June 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

